Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer
© Gunn et al.; licensee BioMed Central Ltd. 2013
Received: 25 October 2012
Accepted: 7 December 2012
Published: 4 January 2013
There is a clinical need for routinely available genomic biomarker testing in newly diagnosed ovarian cancer. In the current study we performed molecular cytogenetics using a validated array based comparative genomic hybridization (array CGH) assay to screen for the presence of predictive and prognostic biomarkers in archival diagnostic tissue from ovarian cancer patients. We hypothesized that biomarkers of high-risk disease would be detectable in tumor samples from patients with treatment refractory, advanced disease, and would be detected less frequently in tumor samples from patients with more favorable outcomes. In addition, we predicted that the use of a genome-wide copy number analysis (CNA) testing platform would enable us to identify novel potentially targetable chromosomal alterations of therapeutic significance in a percentage of cases.
Formalin-fixed paraffin-embedded tissue (FFPE) tumor bank specimens were retrieved from the initial surgical resection for 18 ovarian cancer patients. Molecular cytogenetics was performed by array CGH for the detection of somatic chromosomal alterations associated with high-risk disease including amplifications of the CCNE1 and HER2 genes. Genomic risk stratification results were correlated with available clinical data. CGH data from each patient’s tumor genome was also surveyed for the presence of potentially targetable aberrations. Relevant therapeutic agents and open studies for investigational drugs were reported for each patient.
High-risk genomic alterations were identified in 12/18 (67%) of cases and all patients with high-risk markers had advanced, treatment refractory disease. Three tumors with minimal genomic changes had no high-risk markers and were from patients with Stage I/II disease that had been completely resected and under surveillance for recurrence. Eleven patients (61%) had at least one potentially targetable genomic alteration including CCNE1, HER2, KRAS gene amplifications, and somatic BRCA1 and/or BRCA2 gene deletions. Bi-allelic PTEN gene deletion was detected in one patient’s tumor.
Clinical genomic profiling of ovarian tumors by array CGH augments pathologic grade and stage to help stratify newly diagnosed ovarian cancer into high and low-risk disease. This personalized genomic information can also help guide treatment planning and disease monitoring by identifying novel potentially targetable genomic alterations that can be used by clinicians to choose rational directed therapies for patients with chemo-resistant disease.
Ovarian cancer is a leading cause of cancer deaths in North American women. The majority of cases are diagnosed at an advanced stage, and therapeutic options are generally limited to aggressive surgical resection and adjuvant platinum-based chemotherapy regimens. Histologic subtype, tumor grade, and disease stage are currently used to stratify patients into high versus low-risk disease, and predict response to conventional therapy. Observed heterogeneity of disease course within these risk stratification groups has historically been attributed to the biology of each individual tumor genome, but until recently the underlying DNA alterations driving tumor behavior were not routinely detectable by the clinical laboratory.
It has been known for over two decades that HER2 overexpression is associated with poor survival in ovarian cancer and an estimated 10% of ovarian cancers are reported to be HER2 positive [1, 2]. Curiously HER2 status is still not routinely evaluated as a prognostic/predictive marker in ovarian cancer even in advanced treatment refractory cases. This is particularly remarkable in light of the availability of not only FDA approved diagnostic testing, but also the increasing number of FDA approved anti-HER2 and anti-EGFR family therapies . The low percentage of HER2 positive ovarian cancer cases may be among the reasons why routine HER2 testing is not performed, however NSCLC adenocarcinoma cases are increasingly sent for ALK testing even though the prevalence of ALK positivity is estimated to be only about 5% . With approximately 200,000 ovarian cancer cases a year affecting women worldwide, an estimated 20,000 patients may have undetected HER2 positive ovarian cancer.
Somatic BRCA1 and BRCA2 gene alterations have been reported in sporadic epithelial ovarian cancers including loss of expression, somatic mutations, and LOH (deletions) . Most BRCA gene studies in ovarian cancer have centered around the differential chemosensitivity profile known as “BRCAness syndrome” in selected patients with inherited BRCA1 and BRCA2 mutations who are reported to show enhanced sensitivity to platinum-based anticancer drugs . However, clinicopathologic studies have shown most ovarian cancers with germline BRCA1 and BRCA2 mutations to be morphologically and clinically similar to sporadic ovarian cancer. These findings suggest that the loss of BRCA1 and BRCA2 gene function is important in ovarian carcinogenesis and BRCA genes drive ovarian tumor behavior whether the loss of gene function is caused by germline mutations, somatic alterations, or both. Therefore, detecting somatic alterations is of particular importance in the search for alternative ovarian cancer therapies because recent studies have shown that inhibitors of poly(ADP-ribose) polymerase (PARP) are potential targeted therapies for ovarian cancers with loss of BRCA1 and/or BRCA2 function .
The clinical availability of high-throughput genome wide copy number testing platforms and recently reported predictive/prognostic ovarian cancer biomarkers introduce a new era for risk stratification and treatment planning in ovarian cancer . Biomarker identification has also fueled a growing awareness of increasing opportunities for novel targeted therapies . These new high throughput testing methodologies, can detect multiple ovarian cancer biomarkers including focal amplifications of the HER2 and CCNE1 oncogenes, and somatic deletions of the BRCA1, BRCA2 genes in a single test. Many of these biomarkers can strongly predict disease course and response to therapy, but few have made their way into routine clinical use.
In order to develop a molecular cytogenetics testing strategy that would make genomic analysis of ovarian cancer biomarkers routinely available for our patients, we used clinically validated oligonucleotide and BAC array CGH assays to perform high throughput copy number analysis in archival ovarian tumor tissue from patients with known disease status. Our CGH tests provided a genome-wide survey of CNAs for the identification of known and novel predictive/prognostic biomarkers in each ovarian cancer patient’s tumor. As part of our study, we developed a reporting structure that would clearly and concisely communicate the actionable results to the clinician including prognostic biomarkers, and potential targeted therapeutic options.
Molecular testing methods
Patient selection and tissue retrieval
Archival tumor samples from 18 cases of ovarian cancer with known disease status were retrieved from the START Cancer Center Tumor Bank. The tumor histologic subtypes included one clear cell, one granulosa, and 16 papillary serous carcinomas. Informed written consent was obtained from all patients and samples with accompanying case histories were de-identified for inclusion in the study.
DNA extraction from FFPE tissues
H&E slides were prepared with tumor areas visualized and circled by a pathologist. Targeted tissue areas were captured by slide scraping and following proteinase K digestion, a minimum of 2 μg DNA was isolated using the Promega Maxwell 16, with verification of high molecular weight DNA by agarose gel electrophoresis.
Array-based genomic analysis
Genomic biomarkers analyzed by molecular cytogenetics
High risk biomarkers were defined as: gain or amplification of the CCNE1 or HER2 genes, any high level (ratio > 3.0) oncogene amplification such as MYC or CCND1 among others, and/or PTEN gene deletion. Based on the genomic profiling results, each patient’s tumor genome was stratified as either HIGH RISK GENOMIC MARKERS DETECTED or NO HIGH RISK GENOMIC MARKERS DETECTED with the relevant high-risk markers listed in the report. Each patient’s tumor genome was also surveyed for the presence of other biomarker with potential therapeutic implications and reported as: POTENTIAL THERAPEUTIC TARGETS IDENTIFIED or NO POTENTIAL THERAPEUTIC TARGETS IDENTIFIED. In cases where potential therapeutic targets were identified, relevant therapeutic agents and open studies for investigational drugs were reported for each patient.
Prognostic biomarkers detected by array CGH in 18 cases of ovarian cancer correlated with clinical information
High risk biomarkers
Disease summary and current status
Stage IIIC/serous; Locally advanced disease
Stage IIIC/serous; Disease free under surveillance
Stage IIIC/serous; Non-resectable disease; progressive
CCNE1, CCND1, CCND3, MYC, ETV6
Stage IIIC/clear cell; Progressive non-resectable disease
Stage 1C/granulosa; Disease free under surveillance
Stage IIA/serous; Disease free under surveillance
CCND3, MYC, AKT2,
Stage IIIC/serous; Locally recurrent disease
MYC, JAK2, FGFR3, MYB
Stage IIB/serous; Stable disease following surgery for recurrence
CCNE1, MYC, ETV6
Stage IV at diagnosis; Metastatic to brain; deceased June 2012
Stage IIIC/serous; Recurrent disease
Stage IIIC/serous; Progressive disease
Stage IIIC/serous; Metastatic disease
Stage IV serous/Metastatic to bones and chest; Platinum resistant
Stage III/serous; Progressive local recurrence
Stage 1A/serous; Disease free under surveillance
Stage IIIC/serous; Locally advanced disease
Stage IIIC/serous; Recurrent disease
Stage IIIC/serous; Progressive non-resectable disease
Predictive biomarkers detected by array CGH with associated approved or experimental relevant therapeutics
Cell cycle inhibitor
BMS-387032, flavopiridol, seliciclib, P1446A-05
Lapatinib, trastuzumab, neratinib
PD 0325901, GSK1120212, AS703026, MSC1936369B, AZD6244, ARRY-438162
Early onset breast cancer gene 1
Poly ADP Ribose Polymerase inhibitors (PARP)
AZD2281, ABT-888, MK4827
Early onset breast cancer gene 2
Poly ADP Ribose Polymerase inhibitors (PARP)
AZD2281, ABT-888, MK4827
Bi-allelic PTEN Del
Eight tumors were positive for amplifications of the chromosome 3q26 region that has recently been identified as a significant region of amplification in ovarian tumors from patients with high risk disease and poor outcome. This region contains the MECOM, SnoN/SKiL, and ECT2 genes all of which have been implicated in ovarian cancer pathogenesis. All cases in this study with 3q26 amplification were high grade serous carcinomas .
The advent and recent availability of molecular cytogenetics in the clinical laboratory has added a new tool for genomic pathologists to use when evaluating solid tumors characterized by recurrent amplifications and deletions such as those of the brain, breast, and ovary . We have developed a genome-wide, predictive and prognostic biomarker testing strategy for ovarian cancer that can be performed on a single platform using array CGH analysis of archival tumor DNA. Evaluation of diagnostic tumor tissue from 18 patients and correlation with current disease status revealed high-risk biomarkers to be positive in cases with advanced disease and not detectable in cases with more favorable outcomes. In addition, we identified alternative therapeutic targets in 11 patients with platinum resistant disease.
The use of array CGH as our testing platform allowed a genome-wide view of the chromosomal status of each tumor. Over half of the cases (N=10) were positive for somatic BRCA1 and/or BRCA2 gene deletions. All BRCA deleted cases were serous carcinomas with genome-wide chromosomal instability patterns reminiscent of those seen in triple negative basal-like breast cancers. There was also a high frequency of MYC and CCNE1 gene amplifications. This data is consistent with recently published integrated analysis of human breast cancers showing basal-like breast cancer to be genetically similar to serous ovarian carcinoma . No tumors showed focal TP53 gene deletions in our study. However recent exome capture and sequencing on DNA isolated from 316 serous ovarian carcinomas revealed TP53 mutations in at least 96% of samples [8, 18]. The absence of copy number changes involving TP53 in our study strongly suggests that intragenic point mutations are the primary mechanism by which the protein’s tumor suppressor function is lost in ovarian cancer. Future biomarker test development for ovarian cancer would ideally include a clinical assay for TP53 exome sequencing for detection of specific mutations with clinical prognostic and predictive value.
Three cases with advanced disease were negative for literature derived high-risk biomarkers, however all of these cases were positive for 3q26 gene amplifications. This region has recently been reported to be important for ovarian carcinogenesis and a recurrent region of gene amplification in ovarian cancer . Two of the genes included in the region, MECOM and ECT2, have been associated with ovarian carcinogenesis. The MDS1 and EVI1 complex locus protein EVI1 (MECOM/EVI1) is a proto-oncogene which functions as a transcriptional regulator. EVI1 overexpression has been linked in human acute myelogenous leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelogenous leukemia (CML). Immunostaining studies also show clear evidence of EVI-1 overexpression in some solid tumors including ovarian [19, 20]. Arsenic trioxide (ATO) has been studied as a potential therapy for EVI1 expressing solid tumors but is not currently in clinical trials for ovarian cancer . ECT2 encodes a transforming cell cycle regulator protein highly expressed in ovarian tumors [22, 23]. Ovarian cancer and other solid tumor patients with positive test results for the EV-1 biomarker may be included in future ATO clinical trials in order to determine if their tumors show response to this rational directed therapy.
Molecular cytogenetic profiling of ovarian tumors by array CGH does not replace pathologic stratification of newly diagnosed ovarian cancer. The anatomic pathology report documenting grade and histologic subtype is still the cornerstone of the diagnostic and prognostic workup. However, genomic information about each patient’s tumor can augment traditional pathology findings to assist oncologists in the personalization of treatment planning and disease monitoring. At our institution, anatomic pathologists identify appropriate solid tumor cases for post-diagnostic prognostic marker testing by molecular cytogenetics at the time of diagnosis. Using this pro-active approach, the underlying DNA alterations driving tumor behavior are routinely reported to the oncologist by our clinical laboratory. This information enhances risk stratification and often identifies novel potentially targetable chromosomal alterations of therapeutic significance. In addition, DNA from the primary tumor is stored and can be used for future testing in the event of disease recurrence or metastases. As new prognostic and predictive markers are identified and become clinically available for ovarian cancer, molecular cytogenetics will become part of the routine diagnostic workup enabling oncologists to better predict disease course and choose targeted therapies based on the genomic profile of each individual’s tumor genome.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.